H. Lundbeck A/S Class A · OMXCOP:HLUN_A
H. Lundbeck A/S Class A — Q2 2007 Earnings Presentation
66 slides from H. Lundbeck A/S Class A's earnings presentation, Aug 15, 2007
Slide 1: Investor kit - Q2 2007
Investor kit - Q2 2007 _________________ Q2 2007 release Financial highlights Costs by quarter Sales by quarter Financial presentation Q2 2007
Slide 2: Interim report for the second quarter of 2007
H. Lundbeck A/S Ottiliavej 9 Tel +45 36 30 13 11 E-mail investor@lundbeck.com 2500 Valby - Copenhagen Fax +45 36 43 82 62 www.lundbeck.com Release No 284 15 August 2007 Interim report for the second quarter of 2007 The Supervisory Board of H. Lundbeck A/S today approved the Group’s interim report fo
Slide 3: Financial highlights for the period
Financial highlights for the period In respect of recognition and measurement, the interim report has been prepared in accordance with IFRS and related interpretations of the International Accounting Standards Board (IASB), which are expected to apply for the presentation of financial statements for
Slide 4: Financial forecast for 2007
Financial forecast for 2007 Lundbeck forecasts strong growth in consolidated profit for 2007 relative to 2006. Accordingly, Lundbeck expects a profit from operations of more than DKK 2.5 billion, an EBIT margin of 25% and a level of investment of approximately DKK 650 million. In 2005, Lundbeck acqu
Slide 5: Lundbeck Group revenue
Lundbeck Group revenue Q2 Q2 Growth Growth Q1 2007 2006 in DKK at CER 2007 DKKm DKKm DKKm Cipralex® 1,027 856 20% 18% 990 Lexapro® 641 435 47% 54% 628 Ebixa® 409 337 21% 21% 391 Azilect® 40 17 140% 140% 34 Serdolect® 6 2 222% 214% 10 Other pharmaceuticals 432 495 -13% -13% 465 Other revenue 57 58 -2
Slide 6: Cipralex and Ebixa in Europe
Cipralex® and Ebixa® are still Lundbeck's best-selling pharmaceuticals in Europe in terms of revenue and continue to make positive contributions to growth in Europe, posting growth rates of 11% and 19%, respectively, relative to Q2 2006. At the end of May 2007, Cipralex® held 14.4% of total antidepr
Slide 7: Prepayments from Forest and currency hedging
Prepayments from Forest recorded in Lundbeck’s balance sheet - the difference between the invoiced price and the minimum price of Forest’s inventories - was DKK 935 million at 30 June 2007 compared with DKK 1,070 million at 30 June 2006 and DKK 918 million at 31 March 2007. At 30 June 2007, inventor
Slide 8: Revenue outside Europe and USA; expenses
Revenue outside Europe and the USA rose 36% relative to the year-earlier period. The increase was driven primarily by stronger sales of Cipralex® in several major markets. Expenses Lundbeck’s total expenses, exclusive of net financials and tax, were DKK 1,920 million in Q2 2007, which is on a level
Slide 9: Depreciation/amortisation and net financials
Depreciation/amortisation per Q2 Q2 Growth Q1 expense group 2007 2006 in DKK 2007 DKKm DKKm DKKm Cost of sales 56 56 - 71 Distribution 4 3 11% 4 Administration 22 18 23% 22 Research and development 53 47 12% 50 Total depreciation/amortisation, 135 124 9% 147 Group The number of employees measured as
Slide 10: Net trading income and tax
Net income relating to trading derives from income and expenses from instruments that do not meet the criteria for hedging and is recognised directly under net financials at market value. Tax In the current quarter, a proposal for a new tax reform from the Ministry of Taxation was adopted by the Dan
Slide 11: Cash flows
Cash flows Lundbeck’s operating activities generated a cash inflow of DKK 933 million in Q2 2007, compared with an inflow of DKK 135 million in the year- earlier period and DKK 382 million in Q1 2007. The free cash flow amounted to DKK 779 million in Q2 2007 as compared with DKK -72 million in the s
Slide 12: Patent litigation and development portfolio
The appeal in this case was heard on 9 May 2007 before the U.S. Court of Appeals for the Federal Circuit, and the parties involved are awaiting a decision. The patent at issue in the lawsuit is U.S. Patent No. Re 34,712, which is set to expire in March 2012 and covers escitalopram. United Kingdom At
Slide 13: Desmoteplase, Cipralex study and incentive plans
will be taken on the further development process for desmoteplase and Lundbeck's involvement in the project. On 4 June, the results of a study were published in the journal Current Medical Research and Opinion, showing that Cipralex® (escitalopram) was superior to Cymbalta® (duloxetine) in the acute
Slide 14: Debt plans and Supervisory Board
Debt plans In 2002, a share price based plan for employees of the foreign enterprises was set up, and in 2004 a new share price based plan for key employees of US enterprises was established. The value adjustment at 30 June 2007 of the ”debt plans”, including exercised plans, is recognised as a cost
Slide 15: Management statement
governmental laws and related interpretation thereof and unexpected growth in costs and expenses. Management statement The Supervisory Board and Executive Management have considered and adopted the interim report of H. Lundbeck A/S. The interim report, which is unaudited, has been prepared in accord
Slide 16: Lundbeck contacts
Lundbeck contacts Investors: Media: Jacob Tolstrup Caroline Broge Director, Investor Relations Media Relations Manager Tel +45 36 43 30 79 Tel 36 43 26 38 Tel +1 201 350 0187 ________________________ Stock exchange relase No 284 – 15 August 2007 About Lundbeck H. Lundbeck A/S is an international pha
Slide 17: Appendix 1 – Financial highlights
Appendix 1 – Financial highlights Group 2007 2006 2007 2007 2006 2007 Q2 Q2 Q2 6M 6M 6M DKKm DKKm EURm * DKKm DKKm EURm * FINANCIAL HIGHLIGHTS Revenue 2,611.7 2,198.2 350.5 5,194.4 4,430.7 697.2 Profit from operations 691.7 268.6 92.8 1,349.2 719.4 181.1 Net financials 4.7 (22.8) 0.6 52.3 (98.9) 7.0
Slide 18: Appendix 2 – Income statement
Appendix 2 – Income statement 2007 2006 2007 2006 2006 DKKm Q2 Q2 6M 6M Full year Revenue 2,611.7 2,198.2 5,194.4 4,430.7 9,221.0 Cost of sales 398.4 437.2 895.0 857.2 1,645.8 Distribution costs 590.2 645.8 1,167.7 1,233.5 2,418.7 Administrative expenses 384.1 358.4 760.8 677.8 1,418.9 PROFIT BEFORE
Slide 19: Appendix - Balance sheet
Appendix 3 - Balance sheet DKKm 30.06.2007 30.06.2006 31.12.2006 ASSETS Intangible assets 1,801.4 1,639.5 1,780.7 Property, plant and equipment 3,662.0 3,551.2 3,666.7 Financial assets 633.0 390.1 656.4 Non-current assets 6,096.4 5,580.8 6,103.8 Inventories 1,095.4 1,201.7 1,155.0 Receivables 2,293.
Slide 20: Appendix 4 – Equity
Appendix 4 – Equity Share Share Retained Equity capital premium earnings Group 2007 DKKm DKKm DKKm DKKm Equity at 01.04.2007 1,063.2 172.0 5,889.3 7,124.5 Adjustment, deferred gains/losses, hedging - - 4.5 4.5 Realised gains/losses, hedging - - (22.8) (22.8) Realised gains/losses, trading (transferr
Slide 21: Appendix 5 – Cash flow statement
Appendix 5 – Cash flow statement DKKm 2007 2006 2007 2006 2006 Q2 Q2 6M 6M Full year Cash flows from operating activities 933.4 134.5 1,315.3 428.1 1,394.0 Cash flows from investing activities (154.1) (206.7) (280.8) (302.5) (770.5) Free cash flow 779.3 (72.2) 1,034.5 125.6 623.5 Cash flows from fin
Slide 22: Financial highlights 2001-2007 (by quarter)
Financial highlights 2001-2007 (by quarter) Q1 - 2001 Q2 - 2001 Q3 - 2001 Q4 - 2001 2001 Q1 - 2002 Q2 - 2002 Q3 - 2002 Q4 - 2002 2002 Revenue 1.657 1.918 2.047 2.034 7.656 2.378 2.414 2.281 2.415 9.488 Profit from operations 483 618 648 77 1.826 776 786 649 134 2.345 Finance income, net -80 153 -216
Slide 23: Financial highlights 2005-2006 by quarter
Q1 - 2005 Q2 - 2005 Q3 - 2005 Q4 - 2005 2005 Q1 - 2006 Q2 - 2006 Q3 - 2006 Q4 - 2006 2006 Revenue 2.219 2.285 2.265 2.301 9.070 2.232 2.198 2.248 2.543 9.221 Profit from operations 637 509 543 481 2.170 451 269 630 435 1.784 Finance income, net 43 92 22 -49 108 -76 -23 43 -8 -64 Profit before tax 67
Slide 24: Cost percentage of revenue 2001-2002
Cost percentage of revenue Q1 Q2 Total Q3 Q4 Total DKKmillion 2001 % 2001 % 1H 2001 % 2001 % 2001 % 2001 % Revenue 1.657 1.918 3.575 2.047 2.034 7.656 Production costs 310 19% 320 17% 630 18% 344 17% 396 20% 1.370 18% Distribution costs 350 21% 433 22% 783 22% 428 21% 701 34% 1.912 25% Administrativ
Slide 25: Cost percentage of revenue 2003-2004
Cost percentage of revenue Q1 Q2 Total Q3 Q4 Total DKKm 2003 % 2003 % 1H 2003 % 2003 % 2003 % 2003 % Revenue 2.395 2.555 4.951 2.505 2.486 9.941 Production costs 456 19% 428 17% 885 18% 423 17% 450 18% 1.758 18% Distribution costs 578 24% 659 26% 1.237 25% 597 24% 644 26% 2.478 25% Administrative ex
Slide 26: Cost percentage of revenue 2005-2006
Cost percentage of revenue Q1 Q2 Total Q3 Q4 Total DKKm 2005 % 2005 % 1H 2005 % 2005 % 2005 % 2005 % Revenue 2.219 2.285 4.503 2.265 2.301 9.070 Production costs 412 19% 399 17% 811 18% 384 17% 293 13% 1.488 16% Distribution costs 517 23% 641 28% 1.158 26% 545 24% 634 28% 2.337 26% Administrative ex
Slide 27: Cost percentage of revenue 2007
Cost percentage of revenue Q1 Q2 Total Q3 Q4 Total DKKm 2007 % 2007 % 1H 2007 % 2007 % 2007 % 2007 % Revenue 2.583 2.612 5.194 Production costs 497 19% 398 15% 895 17% Distribution costs 578 23% 590 23% 1.168 22% Administrative expenses 377 15% 384 15% 761 15% Research & Dev. Costs 473 18% 549 21% 1
Slide 28: Revenue by quarter (DKKm)
Revenue by quarter (DKKm) Europe FY 2003 Qtr1 04 Qtr2 04 H1 04 Qtr3 04 Qtr4 04 FY 2004 Qtr1 05 Qtr2 05 H1 05 Qtr3 05 Qtr4 05 FY 2005 Qtr1 06 Qtr2 06 H1 06 Qtr3 06 Qtr4 06 FY 2006 Qtr1 07 Qtr2 07 H1 07 Cipralex® 579 306 339 645 381 377 1.404 429 534 963 557 611 2.131 670 697 1.367 686 713 2.766 759 7
Slide 29: Investor Presentation – Financial Results
Investor Presentation Q2 2007 Financial Results
Slide 30: Safe Harbour Statement
Safe Harbour Statement This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product introductions, product approvals and financial performance. Such forward-looking statements are subject to risks, uncertainties and inaccurate
Slide 31: Lundbeck is an international pharmaceutical company specializing in CNS disorders
Lundbeck is an international pharmaceutical company specializing in central nervous system disorders Facts on Lundbeck: Æ Founded by Hans Lundbeck in 1915 Æ An integrated company with core competencies in research, development, production, marketing and sales Æ International presence with pharmaceut
Slide 32: CNS: world's biggest niche
CNS: world’s biggest niche (17% of world pharmaceutical sales)… 2006 CNS market Lundbeck focus USDbn 100.7 (+7%) Depression, N6A 20% Psychosis, N5A (2%) CAGR of 13% 1990-2006 Alzheimer’s disease, N7D 17% (+11%) Parkinson’s disease, N4A 5% (+16%) 3% (+12%) Alcohol dependence, N7E 0.1% (+20%) Stroke,
Slide 33: Broad CNS portfolio of products and late-stage projects
… and Lundbeck holds a broad CNS portfolio of current products and projects in late-stage development Launched products Late-stage pipeline Cipralex®, 2002 / Lexapro®, 2002 Depression, N6A (US partner, Forest Labs.) Lu AA 21004, phase II Bifeprunox (Solvay), phase III Psychosis, N5A Serdolect , 2006
Slide 34: Financial figures Q2 2007
Financial figures Q2 2007 2% Cipralex® (+20%) Q2 Q2 16% DKKm 2007 2006 Growth Lexapro® (+47%) 0.2% 39% Revenue 2,612 2,198 19% 2% Ebixa® (+21%) Azilect® (+140%) R&D (21% of 549 488 13% revenue) 16% Serdolect® (+222% ) EBIT 692 269 158% Other (-13%) pharmaceuticals EBIT margin 26.5% 12.2% 117% Other
Slide 35: Optimizing efforts in Europe and expansion in US and Asia
Optimizing efforts in Europe and expansion in US and Asia Europe Asia R&D R&D USA Located in Denmark – Focusing on psychiatric and Late stage R&D neurological diseases development program Located in NJ – Focusing with escitalopram in SALES on depression and anxiety Japan Fully fledged CNS sales SALE
Slide 36: Improving European profitability continuously
Improving European profitability continously SG&A margin DKKm / FTE in Europe 6000 60% Ongoing targeting programme is lowering the number of sales 4000 40% reps in Europe Increasing revenues with a focus on cost structure is lowering the SG&A margin in 2000 20% Lundbeck’s subsidiaries In effec
Slide 37: Branded market position - three leading compounds
Branded market position - Lundbecks three leading compounds Cipralex®/Lexapro® Ebixa® (memantine)** USA Europe #1 in volume (May 07) #2 in volume (May 07) #2 in value (May 07) #2 in value (May 07) Europe International Markets* #1 in volume (Q1 07) #1 in volume (May 07) #2 in value (Q1 07) #2 in valu
Slide 38: Cipralex / Lexapro market share growth
Cipralex® / Lexapro® - growth in market share as well as underlying market growth Antidepressant market Europe USA Market share, value – market growth, volume Market share, value – market growth, volume 25% 25% Combined 22.4% Combined 17.6% 20% 20% Cipralex® 14.4% Lexapro® 22.1% 15% 15% 10% 10% 5% 5
Slide 39: Ebixa - second largest product
Ebixa® - Lundbecks second largest product Anti-alzheimers market shares Europe Market share, value – market growth, volume 25% Combined 23.5% 40% Ebixa® available for patients 20% diagnosed with moderate to 30% severe Alzheimers Disease Ebixa® 15.3% 15% Memantine is the second 20% most prescribe
Slide 40: Azilect - launched in more than 20 countries
Azilect® - launched in more than 20 countries Anti-parkinsons market shares Europe Market share, value – market growth, volume 6% 12% Lundbeck has launched Azilect® in Azilect® 4.1% more than 20 countries 4% 8% Once daily treatment Approved for monotherapy and adjunct therapy with levodopa 2%
Slide 41: Launch of new compound – Serdolect
Launch of new compound – Serdolect® Value conversion Value conversion driving growth Europe – antipsychotic market in volume in European market DDDm 1500 Expected launch in Underlying growth in atypical 50% antipsychotics: +14% approximately 20 countries in 46% 1000 2007 500 Atypical, DDDm Ser
Slide 42: Financial guidance and significant news flow
Financial guidance and significant news flow Financial guidance Significant news flow (excl. potential writedown of desmoteplase DKK 99 million) 2006 actual 2007 guidance Lu AA21004 DKK 1,784 More than Phase II data to be announced by the EBIT million DKK 2.5 billion end of 2007 EBIT New drug cand
Slide 43: Pharmaceuticals in clinical development
Pharmaceuticals in clinical development Indication Development step Registration Expected Compound Activity Phase I Phase II Phase III application launch Schizophrenia Dopamin/ Bifeprunox serotonin 2009+ Stroke Desmoteplase Plasminogen activator 2009+ Alcohol dependence Specific opioid receptor Nalm
Slide 44: Bifeprunox (phase III) for schizophrenia
Late stage pipeline – Bifeprunox (phase III) for the treatment of schizophrenia Bifeprunox is a latest generation atypical antipsychotic Inlicensed from Solvay in Belgium and is jointly developed with Solvay and Wyeth (North American rights) Strategic fit: Fits well into Lundbeck’s position wi
Slide 45: Desmoteplase (phase III) for ischaemic stroke
Late stage pipeline - Desmoteplase (phase III) for the treatment of ischaemic stroke Potentially first compound to treat patients Prevalence within an up to 9 hours treatment window Stroke patients, mio. Inlicensed from PAION, Germany 0,9 0,6 0,6 0,6 0,2 0,3 Lundbeck holds world wide rights ex
Slide 46: Nalmefene for alcohol dependence
Late stage pipeline - Nalmefene for the treatment of alcohol dependence Potentially new treatment paradigme Prevalence Inlicensed from BioTie, Finland Estimated 5-6% of population suffers from Lundbeck holds world wide rights alcohol abuse or heavy drinking excluding North America, Mexico, UK,
Slide 47: Appendix
The specialist in psychiatry J wndbeck and pioneer in neurology
Slide 48: More information please contact Investor Relations
More information please contact Investor Relations Jacob Tolstrup Director, Investor Relations Tel: + 1 201 350 0187 + 45 36 43 30 79 Fax: + 1 201 261 0623 jtl@lundbeck.com Page 20
Slide 49: Lundbeck share
Lundbeck share Share information: Trading code: Free float (approximately 62m Reuters (LUN.CO) / Bloomberg (LUN DC) shares) is traded 2+ times over ISIN Number DK0010287234 Unsponsored ADR programmes annually (daily trade of HLUKY, CUSIP 40422M107 approximately 0.7m) Index examples: End of
Slide 50: Revenue – by product / by region
Revenue – by product / by region International Total Europe USA Markets Q2 Q2 Q2 Q2 Q2 Q2 Q2 Q2 DKKm 2007 2006 2007 2006 2007 2006 2007 2006 Total revenue 2,612 2,198 1,490 1,400 641 430 424 311 Growth 19% 6% 49% 36% Cipralex® 1,027 856 772 697 - - 255 159 Growth 20% 11% 61% Lexapro® 641 435 - - 641
Slide 51: Revenue, 5 year figures
Revenue, 5 year figures Revenue, DKK million Growth, % 2002 2003 2004 2005 2006 2003 2004 2005 2006 Total revenue 9,488 9,941 9,733 9,070 9,221 5% -2% -7% 2% Cipralex® 78 645 1,661 2,625 3,508 729% 157% 58% 34% Lexapro® 777 1,928 2,420 2,552 1,923 148% 26% 5% -25% Ebixa® 29 286 722 1,105 1,361 893%
Slide 52: Revenue, quarterly figures
Revenue, quarterly figures Revenue, DKK million Growth, Y/Y, % Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2006 2006 2007 2007 2006 2006 2007 2007 Total revenue 2,248 2,543 2,583 2,612 -1% 10% 16% 19% Cipralex® 878 937 990 1,027 27% 26% 18% 20% Lexapro® 479 525 628 641 -21% -16% 30% 47% Ebixa® 339 374 391 409 16% 22% 2
Slide 53: Cost, 5 year figures
Cost, 5 year figures DKK million Growth, Y/Y, % 2002 2003 2004 2005 2006 2003 2004 2005 2006 Revenue 9,488 9,941 9,733 9,070 9,221 5% -2% -7% 2% Production costs 1,818 1,758 1,725 1,488 1,646 -3% -2% -14% 11% Distribution costs 2,458 2,478 2,302 2,337 2,419 1% -7% 2% 4% Administration costs 1,323 1,
Slide 54: Cost, quarterly figures
Cost, quarterly figures DKK million Growth, Y/Y, % Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 2006 2006 2007 2007 2006 2006 2007 2007 Revenue 2,248 2,543 2,583 2,612 -1% 10% 16% 19% Production costs 372 417 497 398 -3% 42% 18% -9% Distribution costs 500 685 578 590 -8% 8% -2% -9% Administration costs 322 419 377 384 -
Slide 55: USD hedging on a rolling basis
Lundbeck hedge the USD on a rolling basis up to 12 months ahead – 2007 USD hedge rate of 5.75 Actual rates Forward rates 10 9 8 7.90 7 6.68 6 6.00 5.89 5.88 5.76 5.70 5.67 5.52 5.51 5 Quarterly figures 4 '03 '04 '05 '06 Q1 Q2 Q3 Q4 Q1 Q2 07 07 07 07 08 08 Average US$ exchange rate Average hedging US
Slide 56: Recognition of income from Forest
Lundbeck recognition of income from Forest Settlement to full royalty P&L Expected sales price Balance P&L (prepayment at USD spot at bulk delivery) Minimum price P&L* At bulk delivery At US sales * Hedging effect at bulk delivery recognised on P&L: Gain/loss from difference in delivery at expected
Slide 57: Depression: Cipralex / Lexapro best-in-class
Cipralex® / Lexapro® - best-in-class Comparator Presented Main outcome Venlafaxine XR SCNP, April 2003 Escitalopram was at least as effective and was better tolerated than (Effexor) venlafaxine XR.Escitalopram treated patients reached sustained response and remission significantly faster. Venlafaxin
Slide 58: Anxiety: Cipralex / Lexapro best-in-class
Cipralex® / Lexapro® - best-in-class Comparator Presented Main outcome Paroxetine SCNP, April 2003 Escitalopram was significantly superior to paroxetine after 24 weeks of (Paxil) treatment of SAD and showed fewer discontinuation effects. Anxiety Paroxetine ACNP, December 2003 Escitalopram was as eff
Slide 59: Global IP position
Global IP position Europe Bifeprunox: Compound patent in majority of countries to Feb. 2022 Escitalopram: Compound patent in majority of countries to May-June 2014. Process patent in majority of countries to June 2014 Memantine: Data exclusivity until 2012. Use patent in major countries to April 201
Slide 60: Worldwide pharmaceutical market 2006
Worldwide pharmaceutical market 2006 USD 605.1 billion, (+7%) 8% 17% (+7%) 3% (+3%) 5% (+6%) (N) CNS 5% (+4%) (C) Cardiovascular (A) Alimentary (J) Anti-Infectives 6% (+8%) 16% (+5%) (R) Respiratory (L) A+Immun (B) Blood 8% (+5%) (M) Muscolo-Skeletal (G) G.U.& Sex Hormones (D) Dermatologicals Other
Slide 61: Worldwide CNS market 2006
Worldwide CNS market 2006 USD 100.7 billion, (+7%) 7% 5% (16%) 21% (+2%) N6A Antidepressants 3% (+11%) N5A Antipsychotics 3% (-4%) N3A Anti-Epileptics 3% (+12%) N2B Non-Narcotic Analgesics 3% (-5%) N2A Narcotic Analgesics N5B Hypnotics & Sedatives 3% (+6%) N2C Anti-Migraine Preps 17% (+11%) N5C Tran
Slide 62: Alzheimer's market 2006
Alzheimer’s (N7D-2006) – 4.6 bill. USD (+16%) Value Market Shares of N7D Rest of world 15% Europe M12 2006 North Rivastigmine USA M12 2006 America 55% Memantine Galantamine Europe 30% Donepezil 0% 10% 20% 30% 40% 50% 60% Source: IMS Health, May 2007, retail Leading product Marketing Corporation Sale
Slide 63: Depression market 2006
Depression (N6A-2006) – 20.3 bill. USD (+2%) North Value Market shares of N6A America CITALOPRAM Rest of world 67% 11% FLUOXETINE PAROXETINE DULOXETINE Europe M12 2006 USA M12 2006 ESCITALOPRAM BUPROPION SERTRALINE Europe VENLAFAXINE 22% 0% 5% 10% 15% 20% 25% Source: IMS Health, May 2007, retail onl
Slide 64: Anti-Parkinson's market 2006
Anti-Parkinson’s (N4A - 2006) – 3.1 bill. USD (+12%) Value Market Shares of N4A - Europe Europe Europe M12 2006 OTHERS 38% North NMDA ANTAGONISTS America MAOI 29% LEVODOPA DERIVATE DOPAMINE AGONISTS COMT INHIBITORS ANTICHOLINERGICS Rest of world 0% 10% 20% 30% 40% 50% 60% 33% Value Market shares of
Slide 65: Antipsychotics market 2006
Antipsychotics (N5A-2006) – 18.1 bill. USD (+11%) Value Market Shares of N5A North Europe M12 2006 America Aripiprazole USA M12 2006 65% Rest of world Risperidone 11% Olanzapine Amisulpride Clozapine Ziprasidone Europe Quetiapine 25% 0% 5% 10% 15% 20% 25% 30% 35% 40% Source: IMS Health, December 200
Slide 66: Alcohol and stroke fibrinolytics markets 2006
Alcohol (N7E - 2006) – USDm 151 (+20%) Europe 54% North America 28% Rest of world 18% Stroke, Fibrinolytics (B1D - 2006) – USDm 675 (+1%) Europe North 31% America 51% Rest of world 18% Page 38